An interventional study of Tumor biopsy and Blood sample in Solid Tumor, Adult, Solid Tumor, Childhood and Hematologic Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 1 site in France. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.
Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 36th largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2022, is one of 29 with no phase, reaches primary completion later than 28 of the 57 other live ones, and was the 103rd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+
CSL Behring · Sites in France, United States, Belgium and 8 more countries
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+
Quetzal Therapeutics · Sites in France, United States, Italy and 2 more countries
Ages 18–71
Janssen Research & Development, LLC · Sites in France, United States, Australia and 4 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 42 · Phase 3 16 · Phase 4 3
First in 2002; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 106 across the 107 interventional studies, 249 across the 35 observational. Of the 65 that completed or were terminated, 14 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 142 have an industry lead sponsor. The 10 most frequent:
Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.
Gustave Roussy, Cancer Campus, Grand Paris has 2 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Hematologic Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT06350994Assistance Publique - Hôpitaux de ParisEarly Assessment of Cardiac Function After Treatment With CAR-T Cells | 2026-12 |
| NCT05379738Centre Hospitalier Universitaire de NiceImpact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy | 2026-12-10 |
| NCT02074839Institut de Recherches Internationales ServierStudy of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | 2026-12-31 |
| NCT05828459Onward TherapeuticsFirst-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | 2027-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 142 studies in Hematologic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.
The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Tumor biopsy · Procedure: Blood sample · Procedure: Bone marrow sample
3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
Comparison of frequency, phenotype and transcriptional profile of the different immune subsets in the tumor following adoptive cell therapy infusion using spectral flow cytometry and RNA sequencing
Time frame: 3 months following ACT
Objective Response
Defined by RECIST 1.1 score for lymphoma and solid tumors
Time frame: 3 months following ACT
Progression-free survival
Defined as the time between the adoptive cell therapy and progression, or death whatever the cause, whichever occurs first.
Time frame: 5 years after first ACT infusion
Overall survival
Defined as the time between the adoptive cell therapy injection and death whatever the cause
Time frame: 5 years after first ACT infusion
Safety of biopsies procedures (when applicable) graded according to CTCAE v5.0
Time frame: From enrollment to 30 days after the last sample
Started Jun 2022 (actual). Primary completion is estimated for Jul 2027, 60 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 60 months is above that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gustave Roussy, Cancer Campus, Grand Paris →